Literature DB >> 28404070

Pathophysiology of irritable bowel syndrome.

Gerald J Holtmann1, Alexander C Ford2, Nicholas J Talley3.   

Abstract

Traditionally, irritable bowel syndrome has been considered to be a disorder with no known underlying structural or biochemical explanation, but this concept is likely to be outdated. In this Review we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut disorder. There is epidemiological evidence that, in a major subset of patients, gastrointestinal symptoms arise first and only later do incident mood disorders occur. Additionally, possible mechanisms for gut-brain dysfunction have been identified, suggesting primary gut disturbances might be the underlying cause in a subgroup. Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most notably an identified mutation of SCN5A); post-infectious changes, chronic infections and disturbances in the intestinal microbiota; low-grade mucosal inflammation, immune activation, and altered intestinal permeability; disordered bile salt metabolism (in 10-20% of cases with diarrhoea); abnormalities in serotonin metabolism; and alterations in brain function, which could be primary or secondary factors. Identical irritable bowel syndrome symptoms are probably due to different disease processes; grouping patients with this disorder into either diarrhoea-predominant or constipation-predominant subtypes promotes heterogeneity. An approach based on the underlying pathophysiology could help to develop therapies that target causes and ultimately provide a cure for patients with irritable bowel syndrome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28404070     DOI: 10.1016/S2468-1253(16)30023-1

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  95 in total

1.  Rational investigations in irritable bowel syndrome.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Frontline Gastroenterol       Date:  2019-06-06

Review 2.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

3.  Brain Functional Interaction of Acupuncture Effects in Diarrhea-Dominant Irritable Bowel Syndrome.

Authors:  Kai Ma; Yongkang Liu; Wei Shao; Jianhua Sun; Jing Li; Xiaokun Fang; Jing Li; Zhongqiu Wang; Daoqiang Zhang
Journal:  Front Neurosci       Date:  2020-12-15       Impact factor: 4.677

4.  Narrow-Spectrum Antibacterial Agents.

Authors:  Roberta J Melander; Daniel V Zurawski; Christian Melander
Journal:  Medchemcomm       Date:  2017-11-06       Impact factor: 3.597

Review 5.  Lubricin as a Therapeutic and Potential Biomarker in Sepsis.

Authors:  Holly Richendrfer; Gregory D Jay
Journal:  Crit Care Clin       Date:  2019-10-21       Impact factor: 3.598

6.  Effect of probiotics and dietary fiber combined with pinaverium bromide on intestinal flora in patients with irritable bowel syndrome.

Authors:  Han Sun; Xueting Li; Weixu Chen; Fangyuan Jia; Jing Su; Bao Zhang; Xia Wu; Ping Wu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 7.  Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Authors:  Mary-Ann Fitzcharles; Frank Petzke; Thomas R Tölle; Winfried Häuser
Journal:  Drugs       Date:  2021-11-20       Impact factor: 9.546

8.  Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing.

Authors:  Anne-Claire B van Orten-Luiten; Nicole M de Roos; Soumia Majait; Ben J M Witteman; Renger F Witkamp
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-11

9.  Microbiota-neuroimmune cross talk in stress-induced visceral hypersensitivity of the bowel.

Authors:  Isabelle A M van Thiel; Wouter J de Jonge; Isaac M Chiu; Rene M van den Wijngaard
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-04-20       Impact factor: 4.052

10.  Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats.

Authors:  Nikita Hanning; Michelle De Bruyn; Hannah Ceuleers; Tim Boogaerts; Maya Berg; Annemieke Smet; Heiko U De Schepper; Jurgen Joossens; Alexander L N van Nuijs; Joris G De Man; Koen Augustyns; Ingrid De Meester; Benedicte Y De Winter
Journal:  Pharmaceutics       Date:  2021-05-29       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.